US approves 1st drug developed to prevent chronic migraines
TRENTON, N.J. (AP) - U.S. regulators have approved the first drug designed to prevent chronic migraines.
Thursday's action by the Food and Drug Administration clears the monthly shot for sale. Aimovig is the first in a new class of long-acting drugs for preventing migraines. Three other shots are expected to win approval by next year, and several pills are being tested.
Current prevention treatments include pills originally developed for epilepsy and other conditions and the wrinkle reducer Botox, but many patients abandon them because they don't help much or cause serious side effects.
Migraines can cause disabling symptoms: throbbing headaches, nausea and vomiting, and sensitivity to light and sound.
Desktop NewsClick to open Continuous News in a sidebar that updates in real-time.
Officials urge drivers to prepare ahead of holiday traffic Officials urge drivers...
Gas prices in Baton Rouge drop below $2 just in time for...
Massive crash shut down I-10 West for hours Monday
Local food bank may have to turn people away this season
Parish president threatens to build wall over downstream impact from EBR developments